We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

190 hedge funds and large institutions have $389M invested in Vanda Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 16

46% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 52

7% more funds holding

Funds holding: 178 → 190 (+12)

0.54% more ownership

Funds ownership: 97.51% → 98.05% (+0.54%)

16% less call options, than puts

Call options by funds: $354K | Put options by funds: $420K

29% less capital invested

Capital invested by funds: $544M → $389M (-$155M)

Holders
190
Holders Change
+12
Holders Change %
+6.74%
% of All Funds
3.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
76
Reduced
52
Closed
16
Calls
$354K
Puts
$420K
Net Calls
-$66K
Net Calls Change
-$717K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$15.9M
2
BlackRock
BlackRock
New York
+$5.16M
3
Citadel Advisors
Citadel Advisors
Florida
+$4.49M
4
BCM
Bridgeway Capital Management
Texas
+$3.17M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$3.02M

Top Sellers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
-$15.6M
2
EIP
Epoch Investment Partners
New York
-$12.9M
3
PAI
Palo Alto Investors
California
-$10.5M
4
N
Nuveen
North Carolina
-$4.93M
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$3.35M +$152K +15,600 +4%
Two Sigma Investments
27
Two Sigma Investments
New York
$3.3M +$875K +89,847 +25%
Invesco
28
Invesco
Georgia
$2.65M +$542K +55,631 +18%
Principal Financial Group
29
Principal Financial Group
Iowa
$2.63M -$59.5K -6,110 -2%
KAM
30
Krensavage Asset Management
New York
$2.55M +$321K +32,991 +11%
PIM
31
Profit Investment Management
Maryland
$2.48M – – –
CSS
32
Cubist Systematic Strategies
Connecticut
$2.47M +$1.56M +160,162 +92%
BCM
33
Bridgeway Capital Management
Texas
$2.41M +$3.17M +325,600 New
Pacer Advisors
34
Pacer Advisors
Pennsylvania
$2.32M +$799K +82,066 +35%
PAM
35
Panagora Asset Management
Massachusetts
$2.17M +$951K +97,683 +50%
Bank of America
36
Bank of America
North Carolina
$2.11M -$607K -62,314 -18%
FP
37
Foundry Partners
Minnesota
$2.09M +$2.75M +282,268 New
Victory Capital Management
38
Victory Capital Management
Texas
$2.06M -$128K -13,187 -5%
Allspring Global Investments
39
Allspring Global Investments
North Carolina
$1.71M +$389K +39,918 +21%
JP Morgan Chase
40
JP Morgan Chase
New York
$1.64M +$724K +74,323 +51%
Connor, Clark & Lunn Investment Management (CC&L)
41
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.62M +$973K +99,878 +84%
SEI Investments
42
SEI Investments
Pennsylvania
$1.43M +$534K +54,808 +39%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$1.37M +$92.3K +9,481 +5%
Franklin Resources
44
Franklin Resources
California
$1.2M +$5.05K +519 +0.3%
Norges Bank
45
Norges Bank
Norway
$1.18M +$1.55M +159,000 New
State Board of Administration of Florida Retirement System
46
State Board of Administration of Florida Retirement System
Florida
$1.16M -$161K -16,501 -10%
HSA
47
Hussman Strategic Advisors
Maryland
$1.15M – – –
Man Group
48
Man Group
United Kingdom
$1.15M +$299K +30,687 +25%
Massachusetts Financial Services
49
Massachusetts Financial Services
Massachusetts
$1.14M +$31.8K +3,261 +2%
BGIM
50
Brandywine Global Investment Management
Pennsylvania
$1.1M +$1.44M +148,219 New
1
2
3 4 5

VNDA Hedge Fund Activity: Q4 2022 in Review

190 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2022, worth a combined $389M — down 29% from $544M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new VNDA positions and 16 closed out — a net gain of 13 holders — while 76 added to existing stakes and 52 trimmed.

The largest buyer was Millennium Management, adding an estimated $15.9M. The largest seller was Macquarie Group, cutting an estimated $15.6M.

  • 190 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2022, up from 178 in Q3 2022.
  • Funds reported $389M of Vanda Pharmaceuticals stock for Q4 2022, down 29% quarter-over-quarter.
  • 29 funds opened new Vanda Pharmaceuticals positions in Q4 2022 and 16 closed out, a net change of +13 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $15.9M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2022 was Macquarie Group, an estimated $15.6M sold.

Based on aggregated 13F filings for Q4 2022.